1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Castration Resistant Prostatic Cancer: new trials by email Literature Review of Castration Resistant Prostatic Cancer trials Research Report on Castration Resistant Prostatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer Docetaxel intermittent - Castration Resistant Prostatic Cancer | Phase 2 | Terminated | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 6 | 2022-07-29 | 2024-11-22 |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Omeprazole 80 mg twice daily - Prostate Cancer, Refractory Cancer | Phase 2 | Recruiting | Wake Forest University Health Sciences | 50 | 2021-03-05 | 2026-04-13 |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Pembrolizumab, Chemotherapy - Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 26 | 2018-02-20 | 2024-11-20 |
Prostatic Neoplasms, Castration-Resistant (4) · Prostatic Neoplasms (3) · Neoplasms (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplasms (3) · Prostatic Neoplasms (1)
Drug Therapy (1) · Omeprazole (1) · enzalutamide (1) · pembrolizumab (1)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Nuvation Bio Inc. (1) · University of California, San Francisco (1) · Wake Forest University Health Sciences (1)
United States (3) · Australia (1)
David Oh, MD (1) · Kate Mahon (1) · Michael Goodman, MD (1)
P30CA012197 (1), R01CA223484 (1)